ERBB2 and colorectal carcinoma: Furthermore, the DESTINY-CRC01 trial evaluated the efficacy of the antibody-drug conjugate (ADC) trastuzumab deruxtecan (T-DXd) in HER2-positive CRC, demonstrating a promising ORR of 45.3% and a median PFS of 6.9 months [63].